Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) is a Healthcare company (Biotechnology) with a market capitalization of $63M. The Maz Rating grades it against the other companies in its sector.
Neumora Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $0.33, Neumora Therapeutics, Inc. Common Stock trades at 3621.7x sales and 3.1x book value, with an EV/EBITDA of 0.1. Over the last twelve months it generated about $17354 of revenue and a net loss of $216M. It runs a gross margin of 0.0%, an operating margin of -1168393.8% and a net margin of -1190187.5%. It shows return on equity of -320.6%, return on invested capital of -296.6% and a free cash flow yield of -266.2%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 3.69. Over the past 52 weeks the share price ranged from $0.30 to $3.65, with a beta of 3.14.
Neumora Therapeutics, Inc. Common Stock does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy, 1 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Neumora Therapeutics, Inc. Common Stock (NMRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 37.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 59.2% / 30% · Interest income / Revenue 5056.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 37.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 59.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 5056.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 37.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 59.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 5056.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 9.69% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.1% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 5056.3% / 5% | Fail |
| FTSE | Debt / Total Assets 56.4% / 33.33% · (Cash+ST Inv) / Total Assets 90.1% / 33.33% · (Cash+Recv) / Total Assets 90.1% / 33.33% · Interest income / Revenue 5056.3% / 5% | Fail |
No. As of September 2026, Neumora Therapeutics, Inc. Common Stock (NMRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Neumora Therapeutics, Inc. Common Stock is over the AAOIFI limit on Debt / Mkt Cap (36m), (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 5056.3% of each dividend: Neumora Therapeutics, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.